title: Influence of phosphodiesterases and cGMP on cAMP generation and on phosphorylation of phospholamban and troponin I by 5-HT4 receptor activation in porcine left atrium.
abstract: Our objective was to investigate the role of phosphodiesterase (PDE)3 and PDE4 and cGMP in the control of cAMP metabolism and of phosphorylation of troponin I (TnI) and phospholamban (PLB) when 5-HT4 receptors are activated in pig left atrium. Electrically paced porcine left atrial muscles, mounted in organ baths, received stimulators of particulate guanylyl cyclase (pGC) or soluble guanylyl cyclase (sGC) and/or specific PDE inhibitors followed by 5-HT or the 5-HT4 receptor agonist prucalopride. Muscles were freeze-clamped at different moments of exposure to measure phosphorylation of the cAMP/protein kinase A targets TnI and PLB by immunoblotting and cAMP levels by enzyme immunoassay. Corresponding with the functional results, 5-HT only transiently increased cAMP content, but caused a less quickly declining phosphorylation of PLB and did not significantly change TnI phosphorylation. Under combined PDE3 and PDE4 inhibition, the 5-HT-induced increase in cAMP levels and PLB phosphorylation was enhanced and sustained, and TnI phosphorylation was now also increased. Responses to prucalopride per se and the influence thereupon of PDE3 and PDE4 inhibition were similar except that responses were generally smaller. Stimulation of pGC together with PDE4 inhibition increased 5-HT-induced PLB phosphorylation compared to 5-HT alone, consistent with functional responses. sGC stimulation hastened the fade of inotropic responses to 5-HT, while cAMP levels were not altered. PDE3 and PDE4 control the cAMP response to 5-HT4 receptor activation, causing a dampening of downstream signalling. Stimulation of pGC is able to enhance inotropic responses to 5-HT by increasing cAMP levels, while sGC stimulation decreases contraction to 5-HT cAMP independently.
authors.affiliation: Heymans Institute of Pharmacology, Ghent University, Ghent, 9000, Belgium. sabine.weninger@ugent.be
authors.forename: Sabine
authors.initials: S
authors.lastname: Weninger
authors.forename: Joris H
authors.initials: JH
authors.lastname: De Maeyer
authors.forename: Romain A
authors.initials: RA
authors.lastname: Lefebvre
mesh_terms: D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology; D000818:Animals; D016275:Atrial Function / Q000502:physiology; D001572:Benzofurans / Q000494:pharmacology; D002135:Calcium-Binding Proteins / Q000502:physiology*; D000242:Cyclic AMP / Q000502:physiology*; D006152:Cyclic GMP / Q000502:physiology*; D054684:Cyclic Nucleotide Phosphodiesterases, Type 3 / Q000502:physiology*; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4 / Q000502:physiology*; D006325:Heart Atria; D066298:In Vitro Techniques; D008297:Male; D009200:Myocardial Contraction / Q000502:physiology; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D010766:Phosphorylation; D044422:Receptors, Serotonin, 5-HT4 / Q000502:physiology*; D012701:Serotonin / Q000494:pharmacology; D058828:Serotonin 5-HT4 Receptor Agonists / Q000494:pharmacology; D013552:Swine; D019210:Troponin I / Q000502:physiology*; D000099211:Phospholamban
chemical_list: D015056:1-Methyl-3-isobutylxanthine; D001572:Benzofurans; D002135:Calcium-Binding Proteins; D000242:Cyclic AMP; D006152:Cyclic GMP; D054684:Cyclic Nucleotide Phosphodiesterases, Type 3; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4; D010726:Phosphodiesterase Inhibitors; D044422:Receptors, Serotonin, 5-HT4; D012701:Serotonin; D058828:Serotonin 5-HT4 Receptor Agonists; D019210:Troponin I; D000099211:Phospholamban; C406662:prucalopride
references.citation: J Cardiovasc Pharmacol. 2011 Oct;58(4):354-62
references.pmid: 21562429
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 1992 Apr;345(4):382-6
references.pmid: 1320206
references.citation: Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):909-14
references.pmid: 15644445
references.citation: Biochem J. 1988 May 15;252(1):269-73
references.pmid: 2844148
references.citation: Cardiovasc Res. 2008 Jan 15;77(2):353-61
references.pmid: 18006474
references.citation: Free Radic Biol Med. 2008 Jul 1;45(1):73-80
references.pmid: 18433725
references.citation: Circ Res. 2006 Oct 13;99(8):816-28
references.pmid: 17038651
references.citation: J Cell Physiol. 2003 Nov;197(2):284-96
references.pmid: 14502568
references.citation: Physiol Rev. 2007 Jan;87(1):315-424
references.pmid: 17237348
references.citation: J Gen Physiol. 2009 Jun;133(6):571-81
references.pmid: 19433622
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 2012 Jun;385(6):565-77
references.pmid: 22426996
references.citation: Circ Res. 2007 Jun 8;100(11):1569-78
references.pmid: 17556670
references.citation: J Mol Cell Cardiol. 2009 Aug;47(2):304-14
references.pmid: 19345227
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 2005 Jun;371(6):473-9
references.pmid: 16012870
references.citation: Circulation. 2006 May 9;113(18):2221-8
references.pmid: 16651469
references.citation: J Biol Chem. 1993 Dec 15;268(35):26286-95
references.pmid: 7902837
references.citation: Biochem Pharmacol. 2000 Jun 15;59(12):1513-9
references.pmid: 10799647
references.citation: Neurogastroenterol Motil. 2005 Oct;17(5):637-42
references.pmid: 16185301
references.citation: Br J Pharmacol. 2008 Dec;155(7):1005-14
references.pmid: 18846035
references.citation: Cardiovasc Res. 2002 Mar;53(4):852-61
references.pmid: 11922895
references.citation: Pharmacol Ther. 2006 Sep;111(3):674-706
references.pmid: 16960982
references.citation: Br J Pharmacol. 1999 Sep;128(1):206-12
references.pmid: 10498853
references.citation: Cardiovasc Res. 2005 Apr 1;66(1):12-21
references.pmid: 15769444
references.citation: Mol Pharmacol. 2008 Nov;74(5):1453-62
references.pmid: 18703669
references.citation: Biochem J. 1988 Feb 1;249(3):709-14
references.pmid: 2895634
references.citation: Nat Rev Mol Cell Biol. 2003 Jul;4(7):566-77
references.pmid: 12838339
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 1994 Jun;349(6):611-8
references.pmid: 7526225
references.citation: Mol Cell Biochem. 1996 Apr 12-26;157(1-2):171-9
references.pmid: 8739244
references.citation: Br J Pharmacol. 2006 Jan;147(2):140-57
references.pmid: 16331294
references.citation: Curr Opin Pharmacol. 2011 Feb;11(1):87-93
references.pmid: 21342787
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 1990 Nov;342(5):619-22
references.pmid: 2090956
references.citation: Exp Biol Med (Maywood). 2005 Apr;230(4):242-50
references.pmid: 15792945
references.citation: J Physiol. 2002 Apr 15;540(Pt 2):457-67
references.pmid: 11956336
references.citation: Am J Physiol. 1997 Mar;272(3 Pt 2):H1212-9
references.pmid: 9087595
references.citation: Circ Res. 2006 Feb 3;98(2):226-34
references.pmid: 16357307
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 2011 Dec;384(6):543-53
references.pmid: 21901315
references.citation: Br J Pharmacol. 2009 Jan;156(2):237-49
references.pmid: 19154438
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 2009 Apr;379(4):349-59
references.pmid: 19002436
references.citation: Cardiovasc Res. 2003 Nov 1;60(2):355-64
references.pmid: 14613865
references.citation: Nucl Med Biol. 2006 Jul;33(5):593-7
references.pmid: 16843833
references.citation: Cell. 2000 May 12;101(4):365-76
references.pmid: 10830164
references.citation: Cardiovasc Res. 1996 Sep;32(3):622-9
references.pmid: 8881523
references.citation: Cardiovasc Res. 2010 Mar 1;85(4):763-72
references.pmid: 19900965